The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA

References

• Maseroli E, Vignozzi L. Testosterone and vaginal function. Sex Med Rev. 2020;8(3):379–392.
   PubMed Web of Science ®Google Scholar
• Baldassarre M, Perrone AM, Giannone FA, et al. Androgen receptor expression in the human vagina under different physiological and treatment conditions. Int J Impot Res. 2013;25(1):7–11.
   PubMed Web of Science ®Google Scholar
• Burger HG. Androgen production in women. Fertil Steril. 2002;77(Suppl 4):S3–S5.
   PubMed Web of Science ®Google Scholar
• Davis SR. Androgens in premenopausal women and women with premature ovarian insufficiency. Climacteric. 2021;24(5):459–465. Epub 2021 Feb 1.
   PubMed Web of Science ®Google Scholar
• Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause. 2018;25(7):837–847.
   PubMed Web of Science ®Google Scholar
• Simon JA, Davis SR, Althof SE, et al. Sexual well-being after menopause: an International Menopause Society white paper. Climacteric. 2018;21(5):415–427. Epub 2018 Jul 10.
   PubMed Web of Science ®Google Scholar
• Shapiro M. What should guide our patient management of vulvovaginal atrophy? Climacteric. 2019;22(1):38–43. Epub 2018 Nov 19.
   PubMed Web of Science ®Google Scholar
• Hammes SR, Levin ER. Impact of estrogens in males and androgens in females. J Clin Invest. 2019;129(5):1818–1826. Epub 2019 May 1.
   PubMed Web of Science ®Google Scholar
• Cipriani S, Maseroli E, Vignozzi L. 2021. Testosterone in females. In: Mulhall JP, Maggi M, Trost L, editors. Controversies in testosterone deficiency. Cham: Springer.
   Google Scholar
• Traish AM, Vignozzi L, Simon JA, et al. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev. 2018;6(4):558–571.
   PubMed Web of Science ®Google Scholar
• Cipriani S, Maseroli E, Vignozzi L. The role of androgens in sexual health and well-being after menopause: unmet needs and opportunities. Curr Opin Endocr Metab Res. 2022;27:100405.
   Google Scholar
• Maseroli E, Vignozzi L. Are endogenous androgens linked to female sexual function? A systemic review and meta-analysis. J Sex Med. 2022;19(4):553–568. Epub 2022 Feb 25.
   PubMed Web of Science ®Google Scholar
• Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660–4666.
   PubMed Web of Science ®Google Scholar
• Cellai I, Filippi S, Comeglio P, et al. Testosterone positively regulates vagina NO-induced relaxation: an experimental study in rats. J Endocrinol Invest. 2022;45(6):1161–1172. Epub 2022 Jan 24.
   PubMed Web of Science ®Google Scholar
• Maseroli E, Cellai I, Filippi S, et al. Anti-inflammatory effects of androgens in the human vagina. J Mol Endocrinol. 2020;65(3):109–124.
   PubMed Web of Science ®Google Scholar
• Traish AM, Kim SW, Stankovic M, et al. Testosterone increases blood flow and expression of androgen and estrogen receptors in the rat vagina. J Sex Med. 2007;4(3):609–619.
   PubMed Web of Science ®Google Scholar
• Cellai I, Comeglio P, Filippi S, et al. The regulatory effect of sex steroids on the RhoA/ROCK pathway in the rat distal vagina. J Sex Med. 2023;20(1):1–13.
   PubMedGoogle Scholar
• Bertin J, Dury AY, Ouellet J, et al. Localization of the androgen-synthesizing enzymes, androgen receptor, and sex steroids in the vagina: possible implications for the treatment of postmenopausal sexual dysfunction. J Sex Med. 2014;11(8):1949–1961. Epub 2014 Jun 12.
   PubMed Web of Science ®Google Scholar
• Cellai I, Di Stasi V, Comeglio P, et al. Insight on the intracrinology of menopause: androgen production within the human vagina. Endocrinology. 2021;162(2):bqaa219.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. J Sex Med. 2014; Dec11(12):2865–2872. Epub 2014 Aug 25.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Martini E, Cucinella L, et al. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for healthy aging in women. Front Endocrinol (Lausanne). 2019;10:561.
   PubMed Web of Science ®Google Scholar
• Mili N, Paschou SA, Armeni A, et al. Genitourinary syndrome of menopause: a systematic review on prevalence and treatment. Menopause. 2021;28(6):706–716.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Panay N, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016;19(2):188–197. Epub 2015 Nov 19. Erratum in: climacteric. 2016 Apr;19(2):i.
   PubMed Web of Science ®Google Scholar
• Davila GW, Singh A, Karapanagiotou I, et al. Are women with urogenital atrophy symptomatic? Am J Obstet Gynecol. 2003;188(2):382–388.
   PubMed Web of Science ®Google Scholar
• Moral E, Delgado JL, Carmona F, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018;21(2):167–173. Epub 2018 Feb 7.
   PubMed Web of Science ®Google Scholar
• Peters KJ. What is genitourinary syndrome of menopause and why should we care? TPJ. 2021;25(2):1–1.
   Google Scholar
• Gabes M, Knüttel H, Stute P, et al. Measurement properties of patient-reported outcome measures (PROMs) for women with genitourinary syndrome of menopause: a systematic review. Menopause. 2019;26(11):1342–1353.
   PubMed Web of Science ®Google Scholar
• Roy S, Caillouette JC, Roy T, et al. Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. Am J Obstet Gynecol. 2004;190(5):1272–1277.
   PubMed Web of Science ®Google Scholar
• Di Pace D, Portuesi R. Vaginal health index score and urogenital syndrome of menopause. Gazz Med Ital Arch Sci Med. 2018;177:741–744.
   Web of Science ®Google Scholar
• Meisels A. The maturation value. Acta Cytol. 1967;11(4):249.
   PubMed Web of Science ®Google Scholar
• Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61(3):508–516.
   PubMed Web of Science ®Google Scholar
• O’Connell TX, Nathan LS, Satmary WA, et al. Non-neoplastic epithelial disorders of the vulva. Am Fam Physician. 2008;77(3):321–326.
   PubMed Web of Science ®Google Scholar
• The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992.
   PubMed Web of Science ®Google Scholar
• Tadir Y, Gaspar A, Lev-Sagie A, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med. 2017;49(2):137–159. Epub 2017 Feb 21.
   PubMed Web of Science ®Google Scholar
• Mercier J, Morin M, Zaki D, et al. Pelvic floor muscle training as a treatment for genitourinary syndrome of menopause: a single-arm feasibility study. Maturitas. 2019;125:57–62. Epub 2019 Mar 29.
   PubMed Web of Science ®Google Scholar
• Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation of tolerability and safety. Maturitas. 2019;121:93–100. Epub 2018 Nov 28.
   PubMed Web of Science ®Google Scholar
• Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015;22(9):950–963.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243–256.
   PubMed Web of Science ®Google Scholar
• Barton DL, Sloan JA, Shuster LT, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (alliance). Support Care Cancer. 2018;26(2):643–650. Epub 2017 Sep 18.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause. 2009;16(5):897–906.
   PubMed Web of Science ®Google Scholar
• Martel C, Labrie F, Archer DF, et al. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. J Steroid Biochem Mol Biol. 2016;159:142–153. Epub 2016 Mar 10.
   PubMed Web of Science ®Google Scholar
• Mension E, Alonso I, Cebrecos I, et al. Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. Climacteric. 2022;25(5):476–482.
   PubMed Web of Science ®Google Scholar
• Holton M, Thorne C, Goldstein AT. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause. Expert Opin Pharmacother. 2020;21(4):409–415. Epub 2020 Jan 11.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Bouchard C, et al. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas. 2015;81(1):46–56.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Labrie F, Archer DF, et al. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause. 2015;22(12):1289–1295.
   PubMed Web of Science ®Google Scholar
• Archer DF, Labrie F, Montesino M, et al. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10lg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol. 2017;174:1–8.
   PubMed Web of Science ®Google Scholar
• Pitsouni E, Grigoriadis T, Douskos A, et al. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: a systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2018;229:45–56.
   PubMed Web of Science ®Google Scholar
• Kearley-Shiers K, Holloway D, Rymer J, et al. Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: is the evidence sufficient? Post Reprod Health. 2022;28(4):237–243. Epub 2022 Oct 26.
   PubMedGoogle Scholar
• Castelo-Branco C, Mension E, Torras I, et al. Treating genitourinary syndrome of menopause in breast cancer survivors: main challenges and promising strategies. Climacteric. 2023;22:1–6.
   Google Scholar
• Bell RJ, Rizvi F, Islam RM, et al. A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause. 2018;25(6):704–709.
   PubMed Web of Science ®Google Scholar
• Fallah P, Wolfe D, Hutton B, et al. Management of genitourinary symptoms in patients with breast cancer: an updated systematic review of available evidence from randomized trials. Support Care Cancer. 2023;31(2):131.
   PubMed Web of Science ®Google Scholar
• Davis SR, Robinson PJ, Jane F, et al. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab. 2018;103(11):4146–4154.
   PubMed Web of Science ®Google Scholar
• Leder BZ, Leblanc KM, Longcope C, et al. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women. J Clin Endocrinol Metab. 2002;87(12):5449–5454.
   PubMed Web of Science ®Google Scholar